Humanized Mouse and Rat Model Market by Type (Genetic Models, Cell-based Models, Rat Models), Application (Oncology, Immunology, Neuroscience, Toxicology, Infectious Diseases), End User (Pharma, Biotech), and Region - Global Forecast to 2030

icon1
USD 0.41 BN
MARKET SIZE, 2030
icon2
CAGR 8.2%
(2025-2030)
icon3
254
REPORT PAGES
icon4
258
MARKET TABLES

OVERVIEW

humanized-mouse-model-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The humanized mouse and rat model market is projected to reach USD 0.41 billion in 2030 from USD 0.28 billion in 2025, at a CAGR of 8.2%. Growth in the humanized mouse and rat model market is majorly driven by the rising use of humanized models in drug discovery research, rising demand for personalized medicine, government-funded initiatives for cancer research, increasing R&D activities in the pharmaceutical & biotechnology industry.

KEY TAKEAWAYS

  • By Region
    The North America humanized mouse & rat model market accounted for a 47.7% revenue share in 2024.
  • By Type
    By type, the humanized mouse model segment is expected to dominate the market throughout the forecast period.
  • By Application
    By application, the oncology segment is projected to grow at the fastest rate from 2025 to 2030.
  • By End User
    By end user, the pharma & biotech segment is expected to dominate the market throughout the forecast period.
  • Key Players
    Companies like Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US) were identified as some of the star players in the humanized mouse & rat model market (global), given their strong market share and model type footprint.
  • SMEs
    Companies like Xenopat (Spain) and Shanghai Medicilon Inc. (China) among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.

Continuous research is being undertaken to develop treatments for immunodeficiency disorders, cancers, and other rare diseases. A majority of these research studies are highly dependent on animal models. Owing to this, market players continuously focus on innovations in mouse models. Growth in the humanized mouse and rat model market is majorly driven by the Rising use of humanized models in drug discovery research, rising demand for personalized medicine, government-funded initiatives for cancer research, increasing R&D activities in the pharmaceutical & biotechnology industry. However, the high cost of custom humanized models and regulatory compliance for ethical use of animal mode are expected to restrain the growth of this market during the forecast period.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The humanized mouse & rat models market is shifting from basic PBMC-humanized setups to HSC/cytokine/HLA-humanized and organ-chimeric platforms that deliver tighter human relevance for modern modalities. Core buyers—pharma/biotech, CRO/CDMOs, and translational centers—need to de-risk bispecifics/TCEs, cell therapies (CAR-T/NK), ADCs/radioligands, and in vivo gene/RNA editing while compressing study cycle times. Their imperatives are to standardize immune phenotyping, solve delivery & durability (AAV/LNP/non-viral RNP), and embed single-cell, spatial, and multiplex cytokine analytics with harmonized SOPs and GMP cell sourcing. Vendors that package pre-validated I/O-ready cohorts, organ-chimeric options (e.g., humanized liver/islet/skin), imaging (BLI/µCT/MRI), and IND-grade data rooms will win share. For clients’ clients—patients, payers, and regulators—this translates into faster translation, higher technical/regulatory success, more reliable biomarkers for patient stratification, and lower total program costs through fewer late-stage failures.

humanized-mouse-model-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Rising use of humanized models in drug discovery research.
  • Emerging preclinical applications of humanized mouse models.
RESTRAINTS
Impact
Level
  • Introduction of FDA Modernization Act 2.0/3.0
  • Stringent regulatory compliance for ethical use of animal models
OPPORTUNITIES
Impact
Level
  • Emergence of CRISPR in biomedical research.
  • Growing preference for humanized PDX models.
CHALLENGES
Impact
Level
  • Alternative methods for animal testing.
  • Limitations of humanized mouse models.

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Rising use of humanized models in drug discovery research.

The demand for humanized mouse models is increasing in immuno-oncology research, attributed to increased research studies validating their efficacy. Demand for humanized mice models is expected to increase in the drug discovery and development activities associated with cancer immunotherapies. The latest approvals for cancer immunotherapies require the use of well-characterized models for drug discovery activities. Humanized mouse models play a pivotal role in testing the interaction of cancer therapeutic candidates with human systems.

Restraint: Introduction of FDA Modernization Act 2.0/3.0.

The enactment of the FDA Modernization Act 2.0 in December 2022—and the subsequent introduction of the FDA Modernization Act 3.0 in February 2024—signals a significant shift in the regulatory landscape, encouraging the adoption of non-animal alternatives in drug development. These legislative changes promote the use of advanced in vitro models, such as human hepatocytes, HepG2 cells, and iPSC-derived hepatocyte-like cells, as viable alternatives to animal models for preclinical testing.

Opportunity: Emergence of CRISPR in biomedical research.

CRISPR is seen as a revolutionary technology for gene editing. Using the Cas9 enzyme differentiates CRISPR from other forms of genetic modification. CRISPR is used in the development of genetically modified mouse strains, making the process not only quicker but also less expensive. Thus, the emergence of CRISPR as a popular technology is expected to offer potential growth opportunities for market players over the coming years.

Challenge: Alternative methods for animal testing.

Developing efficient and reliable alternatives to animal testing poses significant challenges to the growth of the global humanized mouse and rat model market. The increasing pressure from animal rights activists is compelling research institutes and companies to seek options to minimize the use of animals in research activities. This has further led to the development of several alternatives for testing, such as in vitro methods and models based on human cells and tissue cultures; computerized patient-drug databases and virtual drug trials; computer models and simulations (in silico models); organs-on-chips; stem cell and genetic testing methods; and non-invasive imaging techniques, such as MRI, CT, and microdosing.

humanized-mouse-model-market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Humanized-liver PXB-mice used to evaluate hepatic safety of RNAi therapeutics VIR-2218 and ALN-HBV prior to clinical development in hepatitis B. Human-relevant DMPK/safety readouts for oligos; earlier detection of hepatotoxicity risk and higher translational confidence versus conventional mouse strains, helping de-risk IND decisions.
Collaboration with JAX to compare CD34+ HSC–engrafted NSG/NSG-SGM3 strain variants and characterize human immune-cell reconstitution for immuno-oncology studies (humanized NSG platform selection). Sponsor gets data-driven model selection for bispecifics/IO work (better human immune repertoire, survival window), reducing false negatives/positives and shortening time to a fit-for-purpose humanized model.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The humanized mouse and rat model market operates within a multifaceted ecosystem involving various stakeholders. Each entity plays a critical role in ensuring the development, distribution, and application of these models for advanced biomedical research. Raw materials suppliers provide essential components such as genetic materials, human cells, laboratory reagents, and specialized equipment. Model providers specialize in the development and production of humanized mouse and rat models. End users include pharmaceutical companies, academic institutions, and contract research organizations (CROs). These entities use humanized models for preclinical research activities. Regulatory bodies, such as the FDA (USA), EMA (Europe), and other regional authorities, oversee compliance with ethical standards and research guidelines.

humanized-mouse-model-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

humanized-mouse-model-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Humanized Mouse & Rat Model Market, By Type

As of 2024, humanized mouse model segment held the largest share of the market and will continue leading the market through 2030. The humanized mouse models’ segment is further divided into genetic humanized mouse models and cell-based humanized mouse models. The cell-based humanized mouse models segment includes CD34 humanized mouse models, PBMC humanized mouse models, and BLT humanized mouse models. These models have witnessed a higher demand as these mouse strains support the convenient engraftment of human cells and tissues as compared to other models.

Humanized Mouse & Rat Model Market, By Application

In 2024, oncology application segment is expected to grow at the fastest pace during the forecast period. The high growth rate of this segment can be attributed to the rising research activities and growing funding investments from governments to conduct cancer research studies. Humanized mouse models have significantly contributed to understanding cancer biology, as they help validate gene functions, identify novel cancer genes & tumor biomarkers, understand the molecular and cellular mechanisms underlying tumor initiation, and provide better clinical models to test novel therapeutic strategies.

Humanized Mouse & Rat Model Market, By End User

The pharma & biotech companies segment is expected to dominate the humanized mouse & rat model market through the forecast period. Factors such as the rising expenditure for innovative drug development and the growing preference for personalized medicine are expected to support the growth of the pharmaceutical & biotechnology companies segment

REGION

North America to be the largest revenue generating region in the humanized mouse & rat model market during forecast period

North America dominated the humanized mouse & rat model market with the largest share. The large share of North America is attributed to the increasing production of monoclonal antibodies, continued and responsible use of animals, rising preclinical activities by CROs and pharmaceutical companies, implementation of revised funding plans by the National Institutes of Health (NIH), and growing stem cell research in Canada.

humanized-mouse-model-market Region

humanized-mouse-model-market: COMPANY EVALUATION MATRIX

In the humanized mouse & rat model market key players market matrix, The Jackson Laboratory (Star) leads with a strong market share and extensive model type footprint. The company saw an increase in revenue from driven by the continuous investment in research and development to improve and expand its product offerings. JSR Corporation (Emerging Leader) is gaining visibility with its specialized solutions and tailored solutions for humanize models. The company's expanding its regional presence and caters to a comprehensive portfolio of offerings. The company entered the market with the acquisition of Crown Bioscience International. Crown Bioscience International is a global drug discovery and development services company providing translational platforms to advanced oncology.

humanized-mouse-model-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2024 (Value) USD 0.26 Billion
Market Forecast in 2030 (Value) USD 0.41 Billion
Growth Rate CAGR of 8.2% from 2025-2030
Years Considered 2023-2030
Base Year 2024
Forecast Period 2025-2030
Units Considered Value (USD Billion)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Model Type:
    • Humanized Mouse Models
    • Humanized Rat Models
  • By Humanized Mouse Models:
    • Genetic Humanized Mouse Models
    • Cell-based Humanized Mouse Models
  • By Application:
    • Oncology
    • Immunology & Infectious Diseases
    • Neuroscience
    • Hematopoiesis
    • Toxicology
    • Other Applications
  • By End User:
    • Pharmaceutical & Biotechnology Companies
    • Academic & Research Institutes
    • CROs & CDMOs
Regions Covered North America, Asia Pacific, Europe, Latin America, Middle East, and Africa

WHAT IS IN IT FOR YOU: humanized-mouse-model-market REPORT CONTENT GUIDE

humanized-mouse-model-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Competitive Landscape Analysis Additional profiles of regional/local players, their market position/share, strategies, and service portfolios Insights to uncover market gaps and refine differentiation strategies.
End User Market Assessment Comprehensive list of end users typically engaged in discovery, development & manufacturing of biologics (cell therapy, gene therapy) across targeted regions/countries. Insights on identifying potential customers of humanized mouse & rat model
Region-level Market Share Analysis, Cross-segmental Analysis Cross-segmental analysis between model types and application, region-specific competitive analysis. Insights on White Spaces & Unmet Needs, interconnections and supply chain opportunities.

RECENT DEVELOPMENTS

  • March 2025 : Harbour BioMed announced a global strategic collaboration with AstraZeneca to discover and develop next-generation multi-specific antibodies for immunology, oncology, and beyond. The strategic collaboration includes an option to license multiple programs utilizing Harbour BioMed’s proprietary Harbour Mice fully human antibody technology platform in multiple therapeutic areas and a USD 105 million equity investment by AstraZeneca in Harbour BioMed.
  • Novermber 2024 : Taconic Biosciences, Inc. expanded mouse model production and colony management services with the opening of a new US West Coast facility.
  • August 2023 : The company entered into a four-year agreement with Harlan Holdings Ltd., in which the buyer will have exclusive rights to breed and sell all of the company’s rat and mouse research models within Israel. The company will receive a 2% royalty during this four-year period.

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
27
RESEARCH METHODOLOGY
32
EXECUTIVE SUMMARY
44
PREMIUM INSIGHTS
47
MARKET OVERVIEW
This Section Covers the Market Dynamics, and Upcoming Trends Shaping the Humanized Mouse and Rat Models Market.
50
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Rising use of humanized models in drug discovery research
    - Emerging preclinical applications of humanized mouse models
    - Government-funded initiatives for cancer research
    - Increasing R&D activities in pharmaceutical & biotechnology industry
    RESTRAINTS
    - Introduction of FDA Modernization Act 2.0/3.0
    - Stringent regulatory compliance for ethical use of animal models
    OPPORTUNITIES
    - Growing preference for humanized PDX models
    - Emergence of CRISPR in biomedical research
    CHALLENGES
    - Alternative methods for animal testing
    - Limitations of humanized mouse models
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.4 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024
    AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT AND FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - CRISPR-Cas9
    - Tissue engineering
    - In vivo imaging
    COMPLEMENTARY TECHNOLOGIES
    - 3D cell culture
    - Organs-on-Chips
    - Biomarker discovery
    ADJACENT TECHNOLOGIES
    - Proteomics
    - Microfluidics
    - Regenerative medicine
  • 5.10 PATENT ANALYSIS
  • 5.11 TRADE ANALYSIS
  • 5.12 KEY CONFERENCES AND EVENTS, 2025–2026
  • 5.13 REGULATORY LANDSCAPE
    REGULATORY FRAMEWORK
    NORTH AMERICA
    EUROPE
    ASIA PACIFIC
    - China
    - Japan
    - India
    - Australia
    LATIN AMERICA
    MIDDLE EAST & AFRICA
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.14 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA, BY END USER
  • 5.16 IMPACT OF AI ON HUMANIZED MOUSE AND RAT MODEL MARKET
    INTRODUCTION
    MARKET POTENTIAL OF AI IN HUMANIZED MOUSE AND RAT MODELS
    AI USE CASES
    KEY COMPANIES IMPLEMENTING AI
    FUTURE OF GENERATIVE AI IN HUMANIZED MOUSE AND RAT MODEL MARKET
HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE
Market Assessment for Humanized Mouse and Rat Models Market, By Type: Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
89
  • 6.1 INTRODUCTION
  • 6.2 HUMANIZED MOUSE MODELS
    GENETIC HUMANIZED MOUSE MODELS
    - Advancements in genetical engineering technologies to drive market
    CELL-BASED HUMANIZED MOUSE MODELS
    - CD34 humanized mouse models
    - PBMC humanized mouse models
    - BLT humanized mouse models
  • 6.3 HUMANIZED RAT MODELS
    PREFERENCE FOR SRG RAT MODELS FOR RESEARCH STUDIES WITH LARGE SAMPLE SIZE SUPPORTS THE SEGMENT GROWTH
HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER
End User-specific Market Assessment for Humanized Mouse and Rat Models Market: Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
107
  • 7.1 INTRODUCTION
  • 7.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    GROWING ADOPTION OF HU-MICE MODELS IN VACCINE DEVELOPMENT TO BOOST SEGMENT GROWTH
  • 7.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS
    OUTSOURCING OF DRUG DISCOVERY SERVICES BY PHARMA & BIOTECH COMPANIES TO PROPEL MARKET
  • 7.4 ACADEMIC & RESEARCH INSTITUTES
    SUPPORTIVE FUNDING INVESTMENTS FOR LIFE SCIENCE RESEARCH TO DRIVE MARKET
HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION
Market Assessment for Humanized Mouse and Rat Models Market, By Type: Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
116
  • 8.1 INTRODUCTION
  • 8.2 ONCOLOGY
    UTILIZATION OF MOUSE MODELS IN CANCER RESEARCH TO DRIVE MARKET
  • 8.3 IMMUNOLOGY AND INFECTIOUS DISEASES
    DEVELOPMENT OF ADVANCED MODELS FOR TREATMENT OF RARE DISEASES TO DRIVE MARKET
  • 8.4 NEUROSCIENCE
    RISING INCIDENCE OF CNS DISORDERS TO DRIVE MARKET
  • 8.5 TOXICOLOGY
    INCREASING CLINICAL TRIALS FOR TOXICOLOGY STUDIES TO SUPPORT MARKET GROWTH
  • 8.6 HEMATOPOIESIS
    RISING DEMAND FOR STEM CELL THERAPY TO DRIVE MARKET
  • 8.7 OTHER APPLICATIONS
HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION
Region and Country-level Assessment for Humanized Mouse and Rat Models Market: Market Sizing (2023-2030) and Forecast to 2030 (Value USD Million)
131
  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK OF NORTH AMERICA
    US
    - Growing research initiatives on mAbs and biosimilars to drive market
    CANADA
    - Government initiatives on stem cell research to drive market
  • 9.3 EUROPE
    MACROECONOMIC OUTLOOK OF EUROPE
    GERMANY
    - Rising pharmaceutical R&D expenditure to drive market
    UK
    - Growing investments in cancer research to drive market
    FRANCE
    - Rising initiatives for genomics research to support market growth
    ITALY
    - Robust pharmaceutical production to fuel market
    SPAIN
    - Rising growth in biotech industry to drive market
    REST OF EUROPE
  • 9.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK OF ASIA PACIFIC
    CHINA
    - High growth in pharmaceutical industry to drive market
    JAPAN
    - Growing research collaborations among pharmaceutical companies to drive market
    INDIA
    - Growth in biotech industry to drive market
    SOUTH KOREA
    - Rising government-funded investments for pharmaceutical R&D to drive market
    AUSTRALIA
    - Rising biomedical research projects to drive market
    REST OF ASIA PACIFIC
  • 9.5 LATIN AMERICA
    GROWING PRESENCE OF PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO PROPEL MARKET
    MACROECONOMIC OUTLOOK OF LATIN AMERICA
  • 9.6 MIDDLE EAST
    GROWING PHARMACEUTICAL MARKET IN COUNTRIES TO SUPPORT MARKET GROWTH
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 9.7 AFRICA
    GROWING PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH
    MACROECONOMIC OUTLOOK FOR AFRICA
COMPETITIVE LANDSCAPE
This Section Covers Strategic Analysis of Key Players, Market Shares (%), Revenue Analysis (USD Million), Competitive Mapping and Benchmarking for Key Players and SMEs/Start-ups
184
  • 10.1 INTRODUCTION
  • 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET
  • 10.3 REVENUE ANALYSIS, 2020−2024
  • 10.4 MARKET SHARE ANALYSIS, 2024
    HUMANIZED MOUSE AND RAT MODEL MARKET
  • 10.5 COMPANY VALUATION AND FINANCIAL METRICS
    FINANCIAL METRICS
  • 10.6 BRAND/PRODUCT COMPARISON
  • 10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - Company footprint
    - Region footprint
    - Type footprint
    - Application footprint
  • 10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES
    - Detailed list of key startups/SMEs
    - Competitive benchmarking of key startups/SMEs
  • 10.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
    EXPANSIONS
COMPANY PROFILES
In-depth Profiling of Key Players and SMEs/Start-ups Operating in the Humanized Mouse and Rat Models Market: Business Overview, Offerings, Recent Developments
205
  • 11.1 KEY PLAYERS
    CHARLES RIVER LABORATORIES
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    THE JACKSON LABORATORY
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    INOTIV
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    GENOWAY
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    TACONIC BIOSCIENCES, INC.
    - Business overview
    - Products offered
    - Recent developments
    JSR CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    CHAMPIONS ONCOLOGY, INC.
    - Business overview
    - Products offered
    JANVIER LABS
    - Business overview
    - Products offered
    - Recent developments
    VITALSTAR BIOTECHNOLOGY
    - Business overview
    - Products offered
    INGENIOUS TARGETING LABORATORY
    - Business overview
    - Products offered
    HARBOUR BIOMED
    - Business overview
    - Products offered
    - Recent developments
    ONCODESIGN SERVICES
    - Business overview
    - Products offered
    PHARMATEST SERVICES
    - Business overview
    - Products offered
  • 11.2 OTHER PLAYERS
    OZGENE PTY LTD.
    CLEA JAPAN, INC.
    ALTOGEN LABS
    REACTION BIOLOGY
    TRANSCURE BIOSERVICES
    CYAGEN
    ARAGEN LIFE SCIENCES LTD.
    BIOCYTOGEN
    GEMPHARMATECH
APPENDIX
248
  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 HUMANIZED MOUSE AND RAT MODEL MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY AND DEMAND-SIDE FACTORS
  • TABLE 3 HUMANIZED MOUSE AND RAT MODEL MARKET: RISK ANALYSIS
  • TABLE 4 HUMANIZED MOUSE AND RAT MODEL MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS
  • TABLE 5 NUMBER OF R&D PRODUCTS, BY INDICATION (2024)
  • TABLE 6 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 (USD MILLION)
  • TABLE 7 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION, 2022–2024 (USD)
  • TABLE 8 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS (HUMANIZED MOUSE MODELS), BY REGION, 2022–2024 (USD)
  • TABLE 9 HUMANIZED MOUSE AND RAT MODEL MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 10 INVESTMENT AND FUNDING ACTIVITY, BY KEY PLAYER, 2021−2025
  • TABLE 11 HUMANIZED MOUSE AND RAT MODEL MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2021–2024
  • TABLE 12 IMPORT DATA FOR LABORATORY MOUSE
  • TABLE 13 EXPORT DATA FOR LABORATORY MOUSE
  • TABLE 14 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY CONFERENCES AND EVENTS, 2025–2026
  • TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
  • TABLE 21 KEY BUYING CRITERIA, BY END USER
  • TABLE 22 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 23 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (THOUSAND UNITS)
  • TABLE 24 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 25 HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 26 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 27 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 28 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 29 GENETIC HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 30 NORTH AMERICA: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 31 EUROPE: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 32 ASIA PACIFIC: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 33 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 34 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 35 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 36 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 37 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 38 CD34 HUMANIZED MODELS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 39 NORTH AMERICA: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 40 EUROPE: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 41 ASIA PACIFIC: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 42 PBMC HUMANIZED MICE MODELS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 43 NORTH AMERICA: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 44 EUROPE: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 46 BLT HUMANIZED MOUSE MODELS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 47 NORTH AMERICA: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 48 EUROPE: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 50 HUMANIZED RAT MODELS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 51 NORTH AMERICA: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 52 EUROPE: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 53 ASIA PACIFIC: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 54 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 55 USE OF HUMANIZED MICE MODELS IN DEVELOPED AND TESTED VACCINES
  • TABLE 56 HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 57 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 58 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 59 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 60 HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 61 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 62 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 64 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 65 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 66 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 67 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 68 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 69 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 70 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 71 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 73 HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 74 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 75 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 77 HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 78 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 79 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 80 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 81 HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 82 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 83 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 84 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 85 HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 86 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 87 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 89 HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 90 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 91 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 92 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 93 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 94 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 95 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 96 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 97 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 98 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 99 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 100 KEY MACROECONOMIC INDICATORS OF NORTH AMERICA
  • TABLE 101 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 102 US: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 103 US: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 104 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 105 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 106 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 107 CANADA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 108 CANADA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 109 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 110 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 111 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 112 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 113 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 114 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 115 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 116 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 117 KEY MACROECONOMIC INDICATORS OF EUROPE
  • TABLE 118 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 119 GERMANY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 120 GERMANY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 121 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 122 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 123 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 124 UK: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 125 UK: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 126 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 127 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 128 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 129 FRANCE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 130 FRANCE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 131 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 132 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 133 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 134 ITALY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 135 ITALY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 136 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 137 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 138 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 139 SPAIN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 140 SPAIN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 141 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 142 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 143 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 144 REST OF EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 145 REST OF EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 146 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 147 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 148 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 149 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 152 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 154 KEY MACROECONOMIC INDICATORS OF ASIA PACIFIC
  • TABLE 155 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 156 CHINA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 157 CHINA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 158 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 159 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 160 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 161 JAPAN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 162 JAPAN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 163 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 164 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 165 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 166 INDIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 167 INDIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 168 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 169 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 170 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 171 SOUTH KOREA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 172 SOUTH KOREA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 173 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 174 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 175 AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 176 AUSTRALIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 177 AUSTRALIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 178 AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 179 AUSTRALIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 180 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 181 REST OF ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 182 REST OF ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 183 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 184 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 185 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 186 LATIN AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 187 LATIN AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 188 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 189 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 190 KEY MACROECONOMIC INDICATORS OF LATIN AMERICA
  • TABLE 191 MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 192 MIDDLE EAST: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 193 MIDDLE EAST: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 194 MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 195 MIDDLE EAST: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 196 KEY MACROECONOMIC INDICATORS OF MIDDLE EAST
  • TABLE 197 AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 198 AFRICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 199 AFRICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 200 AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 201 AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 202 KEY MACROECONOMIC INDICATORS OF AFRICA
  • TABLE 203 STRATEGIES ADOPTED BY KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET, 2021−2024
  • TABLE 204 HUMANIZED MOUSE AND RAT MODEL MARKET: DEGREE OF COMPETITION
  • TABLE 205 HUMANIZED MOUSE AND RAT MODEL MARKET: REGION FOOTPRINT
  • TABLE 206 HUMANIZED MOUSE AND RAT MODEL MARKET: TYPE FOOTPRINT
  • TABLE 207 HUMANIZED MOUSE AND RAT MODEL MARKET: APPLICATION FOOTPRINT
  • TABLE 208 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY STARTUPS/SMES
  • TABLE 209 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPETITIVE BENCHMARKING OF KEY START UPS/SMES
  • TABLE 210 HUMANIZED MOUSE AND RAT MODEL MARKET: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2025
  • TABLE 211 HUMANIZED MOUSE AND RAT MODEL MARKET: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 212 HUMANIZED MOUSE AND RAT MODEL MARKET: EXPANSIONS, JANUARY 2021–MARCH 2025
  • TABLE 213 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
  • TABLE 214 CHARLES RIVER LABORATORIES: PRODUCTS OFFERED
  • TABLE 215 CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 216 CHARLES RIVER LABORATORIES: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
  • TABLE 217 THE JACKSON LABORATORY: COMPANY OVERVIEW
  • TABLE 218 THE JACKSON LABORATORY: PRODUCTS OFFERED
  • TABLE 219 THE JACKSON LABORATORY: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 220 INOTIV: COMPANY OVERVIEW
  • TABLE 221 INOTIV: PRODUCTS OFFERED
  • TABLE 222 INOTIV: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 223 GENOWAY: COMPANY OVERVIEW
  • TABLE 224 GENOWAY: PRODUCTS OFFERED
  • TABLE 225 GENOWAY: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
  • TABLE 226 TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 227 TACONIC BIOSCIENCES, INC.: PRODUCTS OFFERED
  • TABLE 228 TACONIC BIOSCIENCES, INC.: PRODUCT LAUNCHES, JANUARY 2021–JANUARY 2025
  • TABLE 229 TACONIC BIOSCIENCES, INC.: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 230 JSR CORPORATION: COMPANY OVERVIEW
  • TABLE 231 JSR CORPORATION: PRODUCTS OFFERED
  • TABLE 232 JSR CORPORATION: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 233 JSR CORPORATION: EXPANSIONS, JANUARY 2021–JANUARY 2025
  • TABLE 234 CHAMPIONS ONCOLOGY, INC.: COMPANY OVERVIEW
  • TABLE 235 CHAMPIONS ONCOLOGY, INC.: PRODUCTS OFFERED
  • TABLE 236 JANVIER LABS: COMPANY OVERVIEW
  • TABLE 237 JANVIER LABS: PRODUCTS OFFERED
  • TABLE 238 JANVIER LABS: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 239 VITALSTAR BIOTECHNOLOGY: COMPANY OVERVIEW
  • TABLE 240 VITALSTAR BIOTECHNOLOGY: PRODUCTS OFFERED
  • TABLE 241 INGENIOUS TARGETING LABORATORY: COMPANY OVERVIEW
  • TABLE 242 INGENIOUS TARGETING LABORATORY: PRODUCTS OFFERED
  • TABLE 243 HARBOUR BIOMED: COMPANY OVERVIEW
  • TABLE 244 HARBOUR BIOMED: PRODUCTS OFFERED
  • TABLE 245 HARBOUR BIOMED: DEALS, JANUARY 2021–JANUARY 2025
  • TABLE 246 ONCODESIGN SERVICES: COMPANY OVERVIEW
  • TABLE 247 ONCODESIGN SERVICES: PRODUCTS OFFERED
  • TABLE 248 PHARMATEST SERVICES: COMPANY OVERVIEW
  • TABLE 249 PHARMATEST SERVICES: PRODUCTS OFFERED
  • TABLE 250 OZGENE PTY LTD.: COMPANY OVERVIEW
  • TABLE 251 CLEA JAPAN, INC.: COMPANY OVERVIEW
  • TABLE 252 ALTOGEN LABS: COMPANY OVERVIEW
  • TABLE 253 REACTION BIOLOGY: COMPANY OVERVIEW
  • TABLE 254 TRANSCURE BIOSERVICES: COMPANY OVERVIEW
  • TABLE 255 CYAGEN: COMPANY OVERVIEW
  • TABLE 256 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW
  • TABLE 257 BIOCYTOGEN: COMPANY OVERVIEW
  • TABLE 258 GEMPHARMATECH: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 HUMANIZED MOUSE AND RAT MODEL MARKET SEGMENTATION AND REGIONS CONSIDERED
  • FIGURE 2 HUMANIZED MOUSE AND RAT MODEL MARKET: YEARS CONSIDERED
  • FIGURE 3 HUMANIZED MOUSE AND RAT MODEL MARKET: RESEARCH DESIGN
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY RESPONDENT, DESIGNATION, AND REGION
  • FIGURE 5 GLOBAL HUMANIZED MOUSE AND RAT MODEL MARKET SIZE ESTIMATION, 2024
  • FIGURE 6 COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2024
  • FIGURE 7 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF CHARLES RIVER LABORATORIES, 2024
  • FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARIES
  • FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 10 HUMANIZED MOUSE AND RAT MODEL MARKET: CAGR PROJECTIONS, 2025–2030
  • FIGURE 11 HUMANIZED MOUSE AND RAT MODEL MARKET: DATA TRIANGULATION
  • FIGURE 12 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 REGIONAL SNAPSHOT OF HUMANIZED MOUSE AND RAT MODEL MARKET, 2025–2030
  • FIGURE 16 RISING USE OF HUMANIZED MODELS IN DRUG DISCOVERY RESEARCH TO DRIVE MARKET
  • FIGURE 17 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN US IN 2024
  • FIGURE 18 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT DOMINATED MARKET IN 2024
  • FIGURE 20 HUMANIZED MOUSE AND RAT MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21 NUMBER OF CLINICAL TRIALS REGISTERED FOR CANCER IMMUNOTHERAPIES, 2020–2024
  • FIGURE 22 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 23 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)
  • FIGURE 24 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION, 2022–2024 (USD)
  • FIGURE 25 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION, 2022–2024 (USD)
  • FIGURE 26 HUMANIZED MOUSE AND RAT MODEL MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 27 HUMANIZED MOUSE AND RAT MODEL MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 28 HUMANIZED MOUSE AND RAT MODEL MARKET ECOSYSTEM
  • FIGURE 29 INVESTMENT AND FUNDING SCENARIO, 2021–2025
  • FIGURE 30 HUMANIZED MOUSE AND RAT MODEL MARKET: PATENT ANALYSIS, 2014–2024
  • FIGURE 31 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 32 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • FIGURE 33 KEY BUYING CRITERIA, BY END USER
  • FIGURE 34 AI USE CASES
  • FIGURE 35 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2023–2030 (THOUSAND UNITS)
  • FIGURE 36 HUMANIZED MOUSE AND RAT MODEL MARKET: NORTH AMERICA SNAPSHOT
  • FIGURE 37 HUMANIZED MOUSE AND RAT MODEL MARKET: ASIA PACIFIC SNAPSHOT
  • FIGURE 38 REVENUE ANALYSIS OF KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET, 2020−2024
  • FIGURE 39 MARKET SHARE ANALYSIS OF HUMANIZED MOUSE AND RAT MODEL MARKET, 2024
  • FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
  • FIGURE 41 COMPANY VALUATION AND FINANCIAL METRICS, 2024
  • FIGURE 42 HUMANIZED MOUSE AND RAT MODEL MARKET: BRAND/PRODUCT COMPARISON
  • FIGURE 43 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 44 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY FOOTPRINT
  • FIGURE 45 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 46 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)
  • FIGURE 47 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2024)
  • FIGURE 48 INOTIV: COMPANY SNAPSHOT (2024)
  • FIGURE 49 JSR CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 50 CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 51 HARBOUR BIOMED: COMPANY SNAPSHOT (2024)

Methodology

The research study used secondary sources, directories, and databases to identify and collect valuable information to analyze the global humanized mouse and rat model market. Widespread interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level managers of leading market players, and industry consultants, to obtain and verify qualitative and quantitative information and evaluate the growth scenarios of the market. The global market size was estimated through secondary research (top-down and bottom-up), followed by data triangulation with inputs from industry experts to determine the final market size.

Secondary Research

Secondary research was used to identify and collect information for the technical, market-oriented, and commercial study of the humanized mouse and rat model market. The secondary sources used for this study include the American Association for Cancer Research (AACR), American Association for Laboratory Animal Science (AALAS), European Society for Medical Oncology (ESMO), European Association for Cancer Research (EACR), Humanized Mouse Resource (HMR), National Center for Biotechnology Information (NCBI), and Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC).

Academic Journals and Company Websites; corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations were also used to obtain major information about key market players and market segmentation corresponding to industry trends, regional/country-level markets, market developments, and technology prospects. Secondary data was collected and analyzed to determine the market size of the global humanized mouse and rat model market, which was further validated through primary research.

Primary Research

Primary research was conducted after acquiring basic knowledge about the global humanized mouse and rat model market through secondary research. A series of primary interviews were conducted with market experts from the demand side, including professionals from the pharmaceutical and biopharmaceutical industries and academic institutions. Additionally, interviews were held with individuals from the supply side, such as C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners. The primary interviews were conducted across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 80% and 20% of the primary interviews were conducted with supply-side and demand-side participants. This data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The breakdown of the primary respondents is given below.

Humanized Mouse and Rat Model Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Top-down and bottom-up approaches were used to estimate and validate the total size of the humanized mouse and rat model market. These methods were also used extensively to estimate the size of various subsegments in the market.

Humanized Mouse and Rat Model Market

Data Triangulation

After determining the market size from the above estimation process, the total market was divided into several segments and subsegments. Where applicable, data triangulation and market breakdown procedures were employed to complete the overall market engineering process and determine the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from the demand and supply sides.

Market Definition

A humanized mouse and rat model is an immunodeficient organism genetically engineered to study immune responses to drugs or identify potential disease targets. These models are widely used to study human diseases and genes. Researchers in both academia and industry, along with clinicians, extensively use humanized mouse and rat models in their research applications. Humanized mouse and rat models are beneficial tools for immuno-oncology and infectious disease research. They have improved the ability to predict human responses to new therapeutics in clinical development.

Stakeholders

  • Research and consulting firms
  • Biopharmaceutical manufacturers
  • Pharmaceutical manufacturers
  • Mouse model and service companies
  • Government and private research institutes
  • Manufacturers and suppliers of animal care products
  • Clinical research organizations (CROs)
  • Academic and research institutes
  • Venture capitalists
  • Laboratory animal care associations
  • Public and private animal health agencies

Report Objectives

  • To define, describe, and forecast the humanized mouse and rat model market by type, application, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets1 concerning individual growth trends, prospects, and contributions to the overall humanized mouse and rat model market
  • To assess the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments for North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa
  • To profile the key players and analyze their market shares and core competencies2
  • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

 

TABLE OF CONTENTS

METHODOLOGY

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Humanized Mouse and Rat Model Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Humanized Mouse and Rat Model Market

DMCA.com Protection Status